Published on GHDx (https://ghdx.healthdata.org)

Seroprevalence of anti-SARS-CoV-2 IgG at the epidemic peak in French Guiana. Preprint

General Info

Geography 
France (FRA)
French Guiana
Coverage type 
Country
Time period covered 
July, 2020 - July, 2020
Data type
Scientific literature
Summary 

"The overall seroprevalence was 15.4% [9.3%-24.4%] among 480 participants, ranging from 4.0% to 25.5% across the different municipalities. The seroprevalence did not differ according to gender (p=0.19) or age (p=0.51). Among SARS-CoV-2 positive individuals, we found that 24.6% [11.5%-45.2%] reported symptoms consistent with COVID-19."

Keywords 
Blood tests, COVID-19, Disease outbreaks, Infectious diseases, Medical tests

Citation

Authors 
Flamand C, Enfissi A, Bailly S, Sarmento CA, Beillard E, Gaillet M, Michaud C, Servas V, Clement N, Perilhou A, Carage T, Musso D, Carod J-F, Eustache S, Tourbillon C, Boizon E, James S, Djossou F, Salje H, Cauchemez S, Rousset D.
Journal 
medRxiv
Suggested citation 

Flamand C, Enfissi A, Bailly S, Sarmento CA, Beillard E, Gaillet M, Michaud C, Servas V, Clement N, Perilhou A, Carage T, Musso D, Carod J-F, Eustache S, Tourbillon C, Boizon E, James S, Djossou F, Salje H, Cauchemez S, Rousset D.

Seroprevalence of anti-SARS-CoV-2 IgG at the epidemic peak in French Guiana. Preprint. medRxiv. 2020.

 

Source URL:https://ghdx.healthdata.org/record/seroprevalence-anti-sars-cov-2-igg-epidemic-peak-french-guiana-preprint